Involving senior personnel from UCSF and Cal Tech - then dba Calchoun Vision - the firm was SBIR-involved with NIH from very shortly after launching. In February 2017 management formally changed the name of the firm to RxSight. Initially self-supporting - the firm was well funded by external sources from 2010, In July 2021, firm went public as NASDAQ:RXST. Structured around addressing the idea of a light adjustable lens (LAL), the power of which could be changed after implantation in the eye by the safe, non-invasive application of light. The first target tackled had been the field of cataract surgery - specifically eliminating refractive errors following intraocular lens implantation. Now headquartered in Aliso Viejo, California. the RxSight mission has been to revolutionize the premium cataract surgery experience - effectively by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. The firm has commercialized the worlds first and only adjustable intraocular lens (IOL) that is customized after cataract surgery: using a proprietary light treatment that produces precise modifications in lens curvature, RxSights Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision *after* cataract surgery through an office based IOL enhancement.
